| 0.4833 0.013 (2.83%) | 11-29 09:48 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.59 | 1-year : | 0.69 |
| Resists | First : | 0.5 | Second : | 0.59 |
| Pivot price | 0.46  |
|||
| Supports | First : | 0.39 | Second : | 0.33 |
| MAs | MA(5) : | 0.48 |
MA(20) : | 0.44 |
| MA(100) : | 0.76 |
MA(250) : | 1.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.3 |
D(3) : | 86.4 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 2.2 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AKLI ] has closed below upper band by 43.0%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.5 - 0.5 | 0.5 - 0.51 |
| Low: | 0.46 - 0.47 | 0.47 - 0.47 |
| Close: | 0.47 - 0.47 | 0.47 - 0.47 |
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Thu, 09 Nov 2023
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update - Yahoo Finance
Mon, 06 Nov 2023
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue ... - Nasdaq
Thu, 19 Oct 2023
Akili to Host Third Quarter Financial Results Conference Call and ... - Business Wire
Thu, 12 Oct 2023
Employees with ADHD Aren't Reaching Their Full Potential at Work ... - Business Wire
Fri, 06 Oct 2023
Akili Announces Leadership Transition - Business Wire
Thu, 21 Sep 2023
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding ... - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Health Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 2.52e+007 (%) |
| Held by Institutions | 18.4 (%) |
| Shares Short | 92 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.466e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 624.7 % |
| Return on Equity (ttm) | -36.3 % |
| Qtrly Rev. Growth | 1.04e+006 % |
| Gross Profit (p.s.) | 507.44 |
| Sales Per Share | -45.33 |
| EBITDA (p.s.) | -79194.6 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.79 |
| Dividend | 0 |
| Forward Dividend | 74250 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|